Search Results

Data Presented at the AVA Annual Scientific Meeting Shows Significantly Lower Complication and Failure Rates with Access Vascular’s HydroMID® Midline Catheter

Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott’s world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2.